New inhaled therapy for rare lung disease takes first safety steps
NCT ID NCT06429930
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests the safety of a new inhaled drug called L608, which is being developed for pulmonary arterial hypertension (a type of high blood pressure in the lungs). It involves 32 healthy volunteers aged 18 to 65 who will receive either a single dose of L608 or a placebo. The main goal is to check for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NZCR Ltd (New Zealand Clinical Research)
RECRUITINGChristchurch, 8011, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.